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9. SUMMARY OF RESEARCH RESU工:rS
Using proteomic analysis， we previously identified calreticulin (CRT) as a potentially useful urinary marker for 
bladder cance仁 Now，we have also identi自edgamma -synuclein (SNCG) and a soluble isoform of 
catechol-o・methyltransferase(s-COMT) as novel candidates for tumor markers in bladder cancer， by means of 
proteomic analysis. In the process of es匂blishinga superior tumor marker system， we investigated the diagnostic value 
of a combination assay of these three proteins. Voided urine samples were obtained from 112 bladder cancer and 230 
control patients. Urinary CRT， SNCG， and s-COMT were measured as a combined marker by quantitative western blot 
analysis. Relative concentration of each protein was calculated and the diagnostic value of a concomi抱ntexamination 
of these markers was evaluated by receiver operator characteristic analysis. With the best diagnostic cutoff， the overall 
sensitivity of the combined markers was 76.8% (95% confidence interval， 69・81%)with a specificity of 77.4% (72-80%)， 
while those of a single use of CRT were 71.4% and 77.8%， respectively. When evaluated in relation to tumor 
characteristics， such as grade， s匂ge，size， and outcome of urinary cytology， the diagnostic capacity of the combined 
markers was equal to or better than that of CRT in al categories. Concomi泊ntuse of CRT， SNCG， and s.・COMThad
higher sens社ivityfor detection of bladder cancer than did single use of CRT. Our study suggests that use of this panel of 
markers willlmprove the diagnosis of bladder cancer and may allow the development of a protein microarray assay or 
multi-channel enzyme引nkedimmunosorbent assay. 
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